Sonoma Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Sonoma Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $14.29M | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | $12.74M | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | $13.27M | Jun 17, 2024 |
| FY2023 | Mar 31, 2022 | $12.63M | Jun 21, 2023 |
| FY2022 | Mar 31, 2021 | $18.63M | Jul 13, 2022 |
| FY2019 | Mar 31, 2019 | $18.97M | Jul 1, 2019 |
| FY2019 | Mar 31, 2018 | $16.66M | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | $12.83M | Jun 26, 2018 |
| FY2017 | Mar 31, 2016 | $9.37M | Jun 28, 2017 |
| FY2016 | Mar 31, 2015 | $13.85M | Jun 21, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $14.29M | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | $12.74M | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | $13.27M | Jun 17, 2024 |
| FY2023 | Mar 31, 2022 | $12.63M | Jun 21, 2023 |
| FY2022 | Mar 31, 2021 | $18.63M | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | $17.93M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $18.97M | Jul 10, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $5.47M | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | $4.75M | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | $4.48M | Jun 17, 2024 |
| FY2023 | Mar 31, 2022 | $3.99M | Jun 21, 2023 |
| FY2022 | Mar 31, 2021 | $6.56M | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | $8.12M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $8.88M | Jul 10, 2020 |
| FY2019 | Mar 31, 2018 | $7.31M | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | $5.67M | Jun 26, 2018 |
| FY2017 | Mar 31, 2016 | $2.65M | Jun 28, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($3.46M) | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | ($4.84M) | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | ($5.15M) | Jun 17, 2024 |
| FY2023 | Mar 31, 2022 | ($5.09M) | Jun 21, 2023 |
| FY2022 | Mar 31, 2021 | ($3.95M) | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | ($3.31M) | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | ($11.80M) | Jul 10, 2020 |
| FY2019 | Mar 31, 2018 | ($14.33M) | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | $9.27M | Jun 26, 2018 |
| FY2017 | Mar 31, 2016 | ($10.16M) | Jun 28, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($3.71M) | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | ($4.70M) | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | ($4.57M) | Jun 17, 2024 |
| FY2023 | Mar 31, 2022 | ($5.89M) | Jun 21, 2023 |
| FY2022 | Mar 31, 2021 | ($3.45M) | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | ($7.39M) | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | ($11.26M) | Jul 10, 2020 |
| FY2019 | Mar 31, 2018 | ($14.19M) | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | ($12.97M) | Jun 26, 2018 |
| FY2017 | Mar 31, 2016 | ($14.71M) | Jun 28, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.81M | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | $1.87M | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | $207.0K | Jun 17, 2024 |
| FY2023 | Mar 31, 2022 | $125.0K | Jun 21, 2023 |
| FY2022 | Mar 31, 2021 | $555.0K | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | $1.34M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $1.52M | Jul 10, 2020 |
| FY2019 | Mar 31, 2018 | $1.58M | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | $1.58M | Jun 26, 2018 |
| FY2017 | Mar 31, 2016 | $1.81M | Jun 28, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $7.36M | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | $7.58M | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | $8.84M | Jun 17, 2024 |
| FY2023 | Mar 31, 2022 | $9.76M | Jun 21, 2023 |
| FY2022 | Mar 31, 2021 | $9.45M | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | $14.17M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $18.62M | Jul 10, 2020 |
| FY2019 | Mar 31, 2018 | $19.92M | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | $17.07M | Jun 26, 2018 |
| FY2017 | Mar 31, 2016 | $15.56M | Jun 28, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($88.0K) | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | ($2.40M) | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | ($6.15M) | Jun 17, 2024 |
| FY2023 | Mar 31, 2022 | ($4.25M) | Jun 21, 2023 |
| FY2022 | Mar 31, 2021 | ($3.38M) | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | ($4.59M) | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | ($11.72M) | Jul 10, 2020 |
| FY2012 | Mar 31, 2013 | $1.15M | Jun 25, 2013 |
| FY2012 | Mar 31, 2012 | ($4.03M) | Jun 25, 2013 |
| FY2011 | Mar 31, 2011 | ($4.43M) | Jun 21, 2012 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $80.0K | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | $2.0K | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | $269.0K | Jun 17, 2024 |
| FY2023 | Mar 31, 2022 | $137.0K | Jun 21, 2023 |
| FY2022 | Mar 31, 2021 | $179.0K | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | $206.0K | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $100.0K | Jul 10, 2020 |
| FY2019 | Mar 31, 2018 | $187.0K | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | $394.0K | Jun 26, 2018 |
| FY2017 | Mar 31, 2016 | $345.0K | Jun 28, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $13.69M | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | $14.74M | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | $16.23M | Jun 17, 2024 |
| FY2023 | Mar 31, 2022 | $18.85M | Jun 21, 2023 |
| FY2022 | Mar 31, 2021 | $14.99M | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | $14.56M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $14.45M | Jul 10, 2020 |
| FY2019 | Mar 31, 2018 | $19.21M | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | $25.46M | Jun 26, 2018 |
| FY2017 | Mar 31, 2016 | $13.80M | Jun 28, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $9.28M | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | $8.60M | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | $8.25M | Jun 17, 2024 |
| FY2023 | Mar 31, 2022 | $10.15M | Jun 21, 2023 |
| FY2022 | Mar 31, 2021 | $9.62M | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | $8.94M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $3.96M | Jul 10, 2020 |
| FY2019 | Mar 31, 2018 | $3.88M | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | $4.03M | Jun 26, 2018 |
| FY2017 | Mar 31, 2016 | $3.66M | Jun 28, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $4.41M | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | $6.14M | Jun 17, 2025 |
| FY2025 | Mar 31, 2023 | $7.98M | Jun 17, 2025 |
| FY2024 | Mar 31, 2022 | $8.70M | Jun 17, 2024 |
| FY2023 | Mar 31, 2021 | $5.36M | Jun 21, 2023 |
| FY2022 | Mar 31, 2020 | $5.62M | Jul 13, 2022 |
| FY2021 | Mar 31, 2019 | $7.77M | Jul 14, 2021 |
| FY2020 | Mar 31, 2018 | $15.33M | Jul 10, 2020 |
| FY2019 | Mar 31, 2017 | $21.43M | Jul 1, 2019 |
| FY2018 | Mar 31, 2016 | $10.14M | Jun 26, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($197.81M) | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | ($194.35M) | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | ($189.51M) | Jun 17, 2024 |
| FY2023 | Mar 31, 2022 | ($184.36M) | Jun 21, 2023 |
| FY2022 | Mar 31, 2021 | ($179.28M) | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | ($175.33M) | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | ($169.24M) | Jul 10, 2020 |
| FY2019 | Mar 31, 2018 | ($157.44M) | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | ($143.10M) | Jun 26, 2018 |
| FY2017 | Mar 31, 2016 | ($152.38M) | Jun 28, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $5.37M | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | $3.13M | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | $3.82M | Jun 17, 2024 |
| FY2023 | Mar 31, 2022 | $7.40M | Jun 21, 2023 |
| FY2022 | Mar 31, 2021 | $4.22M | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | $3.69M | Jul 14, 2021 |
| FY2021 | Mar 31, 2019 | $3.69M | Jul 14, 2021 |
| FY2020 | Mar 31, 2018 | $10.07M | Jul 10, 2020 |
| FY2019 | Mar 31, 2017 | $17.46M | Jul 1, 2019 |
| FY2018 | Mar 31, 2016 | $7.47M | Jun 26, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Mar 31, 2019 | $334.0K | Jul 1, 2019 |
| FY2018 | Mar 31, 2018 | $262.0K | Jun 26, 2018 |
| FY2017 | Mar 31, 2017 | $172.0K | Jun 28, 2017 |
| FY2014 | Mar 31, 2014 | $147.0K | Jun 30, 2014 |
| FY2012 | Mar 31, 2013 | $2.70M | Jun 25, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (2) | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | (10) | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | (1) | Jun 17, 2024 |
| FY2023 | Mar 31, 2022 | (1) | Jun 21, 2023 |
| FY2015 | Mar 31, 2015 | 0 | Jun 16, 2015 |
| FY2015 | Mar 31, 2014 | 0 | Jun 16, 2015 |
| FY2014 | Mar 31, 2013 | (1) | Jun 30, 2014 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (2) | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | (10) | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | (1) | Jun 17, 2024 |
| FY2023 | Mar 31, 2022 | (1) | Jun 21, 2023 |
| FY2015 | Mar 31, 2015 | 0 | Jun 16, 2015 |
| FY2015 | Mar 31, 2014 | 0 | Jun 16, 2015 |
| FY2014 | Mar 31, 2013 | (1) | Jun 30, 2014 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 1.63M | Jun 17, 2025 |
| FY2025 | Aug 29, 2024 | 1.06M | Jun 17, 2025 |
| FY2025 | Aug 28, 2024 | 21.17M | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | 780,371 | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | 4.93M | Jun 17, 2024 |
| FY2023 | Mar 31, 2022 | 3.10M | Jun 21, 2023 |
| FY2022 | Mar 31, 2021 | 2.09M | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | 1.78M | Jul 14, 2021 |
| FY2020 | Jun 19, 2019 | 1.33M | Jul 10, 2020 |
| FY2020 | Jun 18, 2019 | 11.97M | Jul 10, 2020 |